{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:46Z","timestamp":1793831326330,"version":"4.6.1"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/ASP-PES\/28397\/2017-POCI-01-0145-FEDER-028397"],"award-info":[{"award-number":["PTDC\/ASP-PES\/28397\/2017-POCI-01-0145-FEDER-028397"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["Biocide_for_Biofilm\u2014TDC\/BII-BTI\/30219\/2017\u2014POCI-01-0145-FEDER-030219"],"award-info":[{"award-number":["Biocide_for_Biofilm\u2014TDC\/BII-BTI\/30219\/2017\u2014POCI-01-0145-FEDER-030219"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006111","name":"Minist\u00e9rio da Ci\u00eancia, Tecnologia e Ensino Superior","doi-asserted-by":"publisher","award":["NORTE-01-0145-FEDER-000069"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000069"]}],"id":[{"id":"10.13039\/501100006111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007434","name":"Agencia Nacional de Inovacao SA","doi-asserted-by":"publisher","award":["POCI-01-0247-FEDER-072237"],"award-info":[{"award-number":["POCI-01-0247-FEDER-072237"]}],"id":[{"id":"10.13039\/501100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jare.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T13:00:10Z","timestamp":1635771610000},"page":"89-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Harnessing microbial iron chelators to develop innovative therapeutic agents"],"prefix":"10.1016","volume":"39","author":[{"given":"Marta","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia A.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0005","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00084-16","article-title":"Options and limitations in clinical investigation of bacterial biofilms","volume":"31","author":"Magana","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"6","key":"10.1016\/j.jare.2021.10.010_b0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2006.03.011","article-title":"Mechanisms of antimicrobial resistance in bacteria","volume":"119","author":"Tenover","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jare.2021.10.010_b0015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3389\/fchem.2019.00824","article-title":"Bacterial biofilm eradication agents: a current review","volume":"7","author":"Verderosa","year":"2019","journal-title":"Front Chem"},{"key":"10.1016\/j.jare.2021.10.010_b0020","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a010306","article-title":"Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era","volume":"3","author":"Kostakioti","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0025","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro.2016.94","article-title":"Biofilms: an emergent form of bacterial life","volume":"14","author":"Flemming","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jare.2021.10.010_b0030","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3389\/fmicb.2017.02409","article-title":"Combination strategies to enhance the efficacy of antimicrobial peptides against bacterial biofilms","volume":"8","author":"Grassi","year":"2017","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1128\/MMBR.00013-14","article-title":"Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics","volume":"78","author":"Lebeaux","year":"2014","journal-title":"Microbiol Mol Biol Rev"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0040","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","article-title":"Analysis of the clinical antibacterial and antituberculosis pipeline","volume":"19","author":"Theuretzbacher","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"10.1016\/j.jare.2021.10.010_b0045","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s12275-018-8114-3","article-title":"Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosa","volume":"56","author":"Kang","year":"2018","journal-title":"J Microbiol"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1039\/C9MD00032A","article-title":"Connecting iron acquisition and biofilm formation in the ESKAPE pathogens as a strategy for combatting antibiotic resistance","volume":"10","author":"Post","year":"2019","journal-title":"Med Chem Commun"},{"issue":"5","key":"10.1016\/j.jare.2021.10.010_b0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.chom.2013.04.010","article-title":"Iron in infection and immunity","volume":"13","author":"Cassat","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tibs.2015.11.012","article-title":"Regulators of iron homeostasis: new players in metabolism, cell death, and disease","volume":"41","author":"Bogdan","year":"2016","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.jare.2021.10.010_b0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3389\/fcimb.2013.00080","article-title":"Shared and distinct mechanisms of iron acquisition by bacterial and fungal pathogens of humans","volume":"3","author":"Caza","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0070","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.molmed.2016.10.005","article-title":"Siderophores in iron metabolism: from mechanism to therapy potential","volume":"22","author":"Wilson","year":"2016","journal-title":"Trends Mol Med"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0075","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A red carpet for iron metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jare.2021.10.010_b0080","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.freeradbiomed.2016.10.489","article-title":"Siderophore-mediated iron acquisition and modulation of host-bacterial interactions","volume":"105","author":"Ellermann","year":"2017","journal-title":"Free Radic Biol Med"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0085","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41579-019-0284-4","article-title":"Bacterial siderophores in community and host interactions","volume":"18","author":"Kramer","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jare.2021.10.010_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13568-019-0796-3","article-title":"Comparison of five bacterial strains producing siderophores with ability to chelate iron under alkaline conditions","volume":"9","author":"Ferreira","year":"2019","journal-title":"AMB Expr"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0095","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/1751-7915.12117","article-title":"Siderophores in environmental research: roles and applications","volume":"7","author":"Ahmed","year":"2014","journal-title":"Microb Biotechnol"},{"key":"10.1016\/j.jare.2021.10.010_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2018.01766","article-title":"The siderophore piscibactin is a relevant virulence factor for Vibrio anguillarum favored at low temperatures","volume":"9","author":"Balado","year":"2018","journal-title":"Front Microbiol"},{"issue":"5","key":"10.1016\/j.jare.2021.10.010_b0105","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1128\/JB.188.5.1882-1891.2006","article-title":"The heterologous siderophores ferrioxamine B and ferrichrome activate signaling pathways in Pseudomonas aeruginosa","volume":"188","author":"Llamas","year":"2006","journal-title":"J Bacteriol"},{"issue":"24","key":"10.1016\/j.jare.2021.10.010_b0110","doi-asserted-by":"crossref","first-page":"7055","DOI":"10.1128\/JB.184.24.7055-7057.2002","article-title":"Alcaligin siderophore production by Bordetella bronchiseptica strain RB50 Is not repressed by the BvgAS virulence control system","volume":"184","author":"Brickman","year":"2002","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jare.2021.10.010_b0115","series-title":"Global Environmental Biotechnology","first-page":"61","article-title":"Siderophore alcaligin E production by Alcaligenes eutrophus CH34: features of the ale-operon and application perspectives of alcaligin E for leaching of heavy metals","author":"Gilis","year":"1997"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0120","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1128\/jb.155.3.949-955.1983","article-title":"Expression of hydroxamate and phenolate siderophores by Shigella flexneri","volume":"155","author":"Payne","year":"1983","journal-title":"J Bacteriol"},{"issue":"6","key":"10.1016\/j.jare.2021.10.010_b0125","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/IAI.00117-11","article-title":"Staphylococcus aureus transporters Hts, Sir, and Sst capture iron liberated from human transferrin by staphyloferrin A, staphyloferrin B, and catecholamine stress hormones, respectively, and contribute to virulence","volume":"79","author":"Beasley","year":"2011","journal-title":"Infect Immunity"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0130","first-page":"434","article-title":"Characterization and optimization of bacterium isolated from soil samples for the production of siderophores","volume":"3","author":"Kumar","year":"2017","journal-title":"Res-Effic Technol"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0135","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1128\/iai.48.1.130-138.1985","article-title":"Siderophore activity of pyoverdin for Pseudomonas aeruginosa, Infect","volume":"48","author":"Cox","year":"1985","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0140","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1128\/MMBR.00012-07","article-title":"Siderophore-based iron acquisition and pathogen control","volume":"71","author":"Miethke","year":"2007","journal-title":"Microbiol Mol Biol Rev"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1099\/00221287-139-9-2159","article-title":"Purification of yersiniabactin: a siderophore and possible virulence factor of Yersinia enterocolitica","volume":"139","author":"Haag","year":"1993","journal-title":"J Gen Microbiol"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0150","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.bbamem.2007.07.026","article-title":"Structural biology of bacterial iron uptake","volume":"1778","author":"Krewulak","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"10.1016\/j.jare.2021.10.010_b0155","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1286-4579(02)01640-4","article-title":"Iron acquisition by Gram-positive bacterial pathogens","volume":"4","author":"Brown","year":"2002","journal-title":"Microbes Infect"},{"key":"10.1016\/j.jare.2021.10.010_b0160","series-title":"Encyclopedia of microbiology","first-page":"94","article-title":"Corynebacteria (including diphtheria)","author":"Smith","year":"2009"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0165","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/21505594.2014.1003001","article-title":"Iron limitation enhances acyl homoserine lactone (AHL) production and biofilm formation in clinical isolates of Acinetobacter baumannii","volume":"6","author":"Modarresi","year":"2015","journal-title":"Virulence"},{"key":"10.1016\/j.jare.2021.10.010_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1008995","article-title":"Acinetobacter baumannii can use multiple siderophores for iron acquisition, but only acinetobactin is required for virulence","volume":"16","author":"Sheldon","year":"2020","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol antimicrobial susceptibility testing considerations: the Achilles' heel of the trojan horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"13","key":"10.1016\/j.jare.2021.10.010_b0180","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40265-021-01580-4","article-title":"Cefiderocol: a review in serious gram-negative bacterial infections","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jare.2021.10.010_b0185","first-page":"909","article-title":"Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia Clin","volume":"29","author":"Cappellini","year":"2007","journal-title":"Ther"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0190","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/ajh.23569","article-title":"Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea","volume":"88","author":"Vichinsky","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jare.2021.10.010_b0195","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.2165\/00003495-200767150-00007","article-title":"Deferasirox","volume":"67","author":"Yang","year":"2007","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bmcl.2015.11.094","article-title":"Recent advances in cancer treatment by iron chelators","volume":"26","author":"Corc\u00e9","year":"2016","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jare.2021.10.010_b0205","series-title":"Metal-based anticancer agents","first-page":"62","article-title":"Iron compounds as anticancer agents","author":"Vessieres","year":"2019"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0210","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1040-8428(01)00218-9","article-title":"Iron chelators as therapeutic agents for the treatment of cancer","volume":"42","author":"Richardson","year":"2002","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jare.2021.10.010_b0215","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2174\/092986712800609706","article-title":"Iron chelators for the treatment of cancer","volume":"19","author":"Yu","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jare.2021.10.010_b0220","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.leukres.2007.05.003","article-title":"A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myelopro","volume":"32","author":"Karp","year":"2008","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0225","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.jare.2021.10.010_b0230","first-page":"1741","article-title":"Iron chelation therapy with deferasirox induced complete remission in a patient with chemotherapy-resistant acute monocytic leukemia","volume":"31","author":"Fukushima","year":"2011","journal-title":"Anticancer Res"},{"issue":"7","key":"10.1016\/j.jare.2021.10.010_b0235","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/ja109665t","article-title":"Design, synthesis, and study of a mycobactin\u2212artemisinin conjugate that has selective and potent activity against tuberculosis and malaria","volume":"133","author":"Miller","year":"2011","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jare.2021.10.010_b0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bcp.2019.06.017","article-title":"Enterobactin, an iron chelating bacterial siderophore, arrests cancer cell proliferation","volume":"168","author":"Saha","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0245","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/1462-2920.12527","article-title":"Molecular mechanisms involved in Bacillus subtilis biofilm formation","volume":"17","author":"Mielich-S\u00fcss","year":"2015","journal-title":"Environ Microbiol"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0250","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00253-010-2468-8","article-title":"Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal","volume":"86","author":"Landini","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.jare.2021.10.010_b0255","first-page":"101","article-title":"Quorum sensing and quorum-quenching enzymes","volume":"43","author":"Dong","year":"2005","journal-title":"J Microbiol"},{"issue":"6888","key":"10.1016\/j.jare.2021.10.010_b0260","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/417552a","article-title":"A component of innate immunity prevents bacterial biofilm development","volume":"417","author":"Singh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.jare.2021.10.010_b0265","first-page":"1","article-title":"Involvement of iron in biofilm formation by Staphylococcus aureus","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.jare.2021.10.010_b0270","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1128\/AAC.00778-12","article-title":"In vitro and in vivo biological activities of iron chelators and gallium nitrate against Acinetobacter baumannii","volume":"56","author":"de L\u00e9s\u00e9leuc","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jare.2021.10.010_b0275","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0504266102","article-title":"Iron and Pseudomonas aeruginosa biofilm formation","volume":"102","author":"Banin","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jare.2021.10.010_b0280","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fcimb.2013.00075","article-title":"Pseudomonas aeruginosa adapts its iron uptake strategies in function of the type of infections","volume":"3","author":"Cornelis","year":"2013","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0285","doi-asserted-by":"crossref","DOI":"10.1186\/s12866-020-01727-5","article-title":"Effects of iron on the growth, biofilm formation and virulence of Klebsiella pneumoniae causing liver abscess","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Microbiol"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0290","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1128\/JB.01086-08","article-title":"IscR controls iron-dependent biofilm formation in Escherichia coli by regulating type I fimbria expression","volume":"191","author":"Wu","year":"2009","journal-title":"J Bacteriol"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0295","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nrmicro1994","article-title":"The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria","volume":"6","author":"Pag\u00e8s","year":"2008","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0300","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10534-009-9219-2","article-title":"Siderophores as drug delivery agents: application of the \u201cTrojan Horse\u201d strategy","volume":"22","author":"M\u00f6llmann","year":"2009","journal-title":"Biometals"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0305","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1128\/AAC.00629-13","article-title":"Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa","volume":"57","author":"Tomaras","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0310","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1128\/AAC.00831-15","article-title":"Pharmacodynamic profiling of a siderophore-conjugated monocarbam in Pseudomonas aeruginosa: assessing the risk for resistance and attenuated efficacy","volume":"59","author":"Kim","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0315","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/jac\/dkr013","article-title":"In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii","volume":"66","author":"Russo","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jare.2021.10.010_b0320","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1007\/s00204-017-1994-x","article-title":"Mechanisms of hepatotoxicity associated with the monocyclic \u03b2-lactam antibiotic BAL30072","volume":"91","author":"Paech","year":"2017","journal-title":"Arch Toxicol"},{"issue":"5-6","key":"10.1016\/j.jare.2021.10.010_b0325","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000487441","article-title":"Humanized exposures of cefiderocol, a siderophore cephalosporin, display sustained in vivo activity against siderophore-resistant Pseudomonas aeruginosa","volume":"101","author":"Ghazi","year":"2018","journal-title":"Pharmacology"},{"key":"10.1016\/j.jare.2021.10.010_b0330","doi-asserted-by":"crossref","first-page":"S519","DOI":"10.1093\/cid\/ciz823","article-title":"Cefiderocol: a novel siderophore cephalosporin defeating carbapenem-resistant pathogens","volume":"69","author":"Bonomo","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.jare.2021.10.010_b0335","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0340","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem-resistant Gram-negative Bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0345","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijantimicag.2017.10.008","article-title":"Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model","volume":"51","author":"Ghazi","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jare.2021.10.010_b0350","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx163.1208","article-title":"In vivo efficacy of cefiderocol against carbapenem-resistant Gram-negative Bacilli in murine urinary tract infection models","volume":"4","author":"Matsumoto","year":"2017","journal-title":"Open Forum Infect. Dis."},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0355","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02031-18","article-title":"In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models Antimicrob","volume":"63","author":"Nakamura","year":"2019","journal-title":"Agents Chemother"},{"issue":"7","key":"10.1016\/j.jare.2021.10.010_b0360","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1128\/AAC.03098-15","article-title":"Stability of novel siderophore cephalosporin S-649266 against clinically relevant carbapenemases","volume":"60","author":"Ito-Horiyama","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0365","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains","volume":"60","author":"Kohira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0370","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1128\/AAC.01405-16","article-title":"Siderophore cephalosporin cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa","volume":"60","author":"Ito","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0375","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative Bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.jare.2021.10.010_b0380","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9813","key":"10.1016\/j.jare.2021.10.010_b0390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(11)60283-3","article-title":"Thalassaemia","volume":"379","author":"Higgs","year":"2012","journal-title":"Lancet"},{"issue":"9757","key":"10.1016\/j.jare.2021.10.010_b0395","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jare.2021.10.010_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399406010805","article-title":"Pathophysiology and therapy for haemoglobinopathies. Part II: thalassaemias","volume":"8","author":"Urbinati","year":"2006","journal-title":"Expert Rev Mol Med"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0405","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jare.2021.10.010_b0410","first-page":"411","article-title":"An update on iron chelation therapy","volume":"10","author":"Poggiali","year":"2012","journal-title":"Blood Transfus"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0415","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12185-008-0120-5","article-title":"Body iron metabolism and pathophysiology of iron overload","volume":"88","author":"Kohgo","year":"2008","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0420","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMct1004810","article-title":"Iron-chelating therapy for transfusional iron overload","volume":"364","author":"Brittenham","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jare.2021.10.010_b0425","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ajh.25103","article-title":"The effect of iron chelation therapy on overall survival in sickle cell disease and \u03b2-thalassemia: a systematic review","volume":"93","author":"Ballas","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jare.2021.10.010_b0430","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1046\/j.1365-2141.2002.03554.x","article-title":"The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients","volume":"118","author":"Ceci","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jare.2021.10.010_b0435","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1182\/blood-2003-08-2841","article-title":"Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major","volume":"104","author":"Davis","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jare.2021.10.010_b0440","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","article-title":"A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia","volume":"107","author":"Cappellini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jare.2021.10.010_b0445","first-page":"239","article-title":"A review on iron chelators in treatment of iron overload syndromes","volume":"10","author":"Mobarra","year":"2016","journal-title":"Int J Hematol Stem Cell Res"},{"issue":"9369","key":"10.1016\/j.jare.2021.10.010_b0450","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(03)13309-0","article-title":"Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"361","author":"Nisbet-Brown","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2021.10.010_b0455","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1182\/blood-2006-02-002394","article-title":"Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions","volume":"107","author":"Neufeld","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jare.2021.10.010_b0460","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0268-960X(08)70007-9","article-title":"Long-term efficacy and safety of deferasirox","volume":"22","author":"Cappellini","year":"2008","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0465","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bcmd.2012.10.006","article-title":"Combined chelation therapy with deferasirox and deferoxamine in thalassemia","volume":"50","author":"Lal","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0470","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.bcmd.2014.04.006","article-title":"Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients","volume":"53","author":"Cassinerio","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"14","key":"10.1016\/j.jare.2021.10.010_b0475","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1161\/CIRCULATIONAHA.106.648790","article-title":"A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance","volume":"115","author":"Tanner","year":"2007","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0480","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bcmd.2010.05.005","article-title":"Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone","volume":"45","author":"Lai","year":"2010","journal-title":"Blood Cells Mol Dis"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0485","first-page":"1592","article-title":"The deferiprone and deferasirox combination is efficacious in iron overloaded patients with \u03b2-thalassemia major: a prospective, single center, open-label study, Pediatr. Blood","volume":"62","author":"Totadri","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0490","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4081\/cp.2017.912","article-title":"Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusion-dependent \u03b2-thalassemia major","volume":"7","author":"Karami","year":"2017","journal-title":"Clin Pract"},{"key":"10.1016\/j.jare.2021.10.010_b0495","first-page":"1187","article-title":"Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine","volume":"89","author":"Borgna-Pignatti","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.jare.2021.10.010_b0500","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2002-06-1867","article-title":"Role of deferiprone in chelation therapy for transfusional iron overload","volume":"102","author":"Hoffbrand","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0505","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/pbc.22711","article-title":"Reversible Fanconi syndrome in a pediatric patient on deferasirox, Pediatr","volume":"56","author":"Rheault","year":"2011","journal-title":"Blood Cancer"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0510","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3324\/haematol.2010.034405","article-title":"A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload","volume":"96","author":"Rienhoff","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.jare.2021.10.010_b0515","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1182\/blood-2011-10-386268","article-title":"A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload","volume":"119","author":"Neufeld","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jare.2021.10.010_b0520","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1093\/jac\/dkz290","article-title":"Development of pyridyl thiosemicarbazones as highly potent agents for the treatment of malaria after oral administration","volume":"74","author":"Parkinson","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jare.2021.10.010_b0525","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0037171","article-title":"Antimalarial iron chelator, FBS0701, shows asexual and gametocyte Plasmodium falciparum activity and single oral dose cure in a murine malaria model","volume":"7","author":"Ferrer","year":"2012","journal-title":"PloSOne"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0530","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12094-011-0621-1","article-title":"The role of iron in tumour cell proliferation","volume":"13","author":"Steegmann-Olmedillas","year":"2011","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0535","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms20020273","article-title":"Iron as a central player and promising target in cancer progression","volume":"20","author":"Jung","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2018","key":"10.1016\/j.jare.2021.10.010_b0540","first-page":"394","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0545","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","article-title":"ROS in cancer therapy: the bright side of the moon","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp Mol Med"},{"issue":"23","key":"10.1016\/j.jare.2021.10.010_b0550","doi-asserted-by":"crossref","first-page":"6876","DOI":"10.1158\/1078-0432.CCR-06-1954","article-title":"Chelators at the cancer coalface: desferrioxamine to Triapine and beyond","volume":"12","author":"Yu","year":"2006","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0555","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/pr.57.4.2","article-title":"The evolution of iron chelators for the treatment of iron overload disease and cancer","volume":"57","author":"Kalinowski","year":"2005","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.jare.2021.10.010_b0560","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1535-7163.MCT-05-0384","article-title":"A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase","volume":"5","author":"Shao","year":"2006","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0565","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jinorgbio.2007.10.013","article-title":"Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine","volume":"102","author":"Kolesar","year":"2008","journal-title":"J Inorg Biochem"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0570","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1586\/14737140.2.4.437","article-title":"Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies","volume":"2","author":"Tsimberidou","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jare.2021.10.010_b0575","first-page":"4092","article-title":"Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors","volume":"9","author":"Murren","year":"2003","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0580","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.leukres.2007.01.004","article-title":"Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies","volume":"31","author":"Gojo","year":"2007","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.jare.2021.10.010_b0585","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10637-007-9044-9","article-title":"Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)","volume":"25","author":"Knox","year":"2007","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0590","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3324\/haematol.2013.097246","article-title":"A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms","volume":"99","author":"Zeidner","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.jare.2021.10.010_b0595","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3389\/fonc.2019.01067","article-title":"Randomized phase II trial of Triapine-cisplatin-radiotherapy for locally advanced stage uterine cervix or vaginal cancers","volume":"9","author":"Kunos","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.jare.2021.10.010_b0600","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10637-007-9085-0","article-title":"A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells","volume":"26","author":"Ma","year":"2008","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.jare.2021.10.010_b0605","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00280-008-0890-8","article-title":"A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors","volume":"63","author":"Schelman","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0610","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10637-009-9230-z","article-title":"A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503","volume":"28","author":"Traynor","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.jare.2021.10.010_b0615","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1182\/blood-2004-03-0868","article-title":"Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment","volume":"104","author":"Yuan","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jare.2021.10.010_b0620","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3390\/ijms17091435","article-title":"The iron chelator, Dp44mT, effectively inhibits human oral squamous cell carcinoma cell growth in vitro and in vivo","volume":"17","author":"Lee","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.jare.2021.10.010_b0625","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s00011-017-1067-x","article-title":"Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT), an anticancer agent, exerts an anti-inflammatory effect in activated human mast cells","volume":"66","author":"Nam","year":"2017","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.jare.2021.10.010_b0630","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1124\/mol.111.073627","article-title":"Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer","volume":"80","author":"Kovacevic","year":"2011","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jare.2021.10.010_b0635","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.phrs.2015.08.013","article-title":"The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the \u201cTriad of Death\u201d in cancer by Di-2-pyridylketone thiosemicarbazones","volume":"100","author":"Jansson","year":"2015","journal-title":"Pharmacol Res"},{"issue":"16","key":"10.1016\/j.jare.2021.10.010_b0640","doi-asserted-by":"crossref","first-page":"7230","DOI":"10.1021\/jm300768u","article-title":"Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo","volume":"55","author":"Lovejoy","year":"2012","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jare.2021.10.010_b0645","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1124\/mol.112.078964","article-title":"Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect","volume":"82","author":"Quach","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jare.2021.10.010_b0650","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-016-0330-x","article-title":"The novel thiosemicarbazone, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), inhibits neuroblastoma growth in vitro and in vivo via multiple mechanisms","volume":"9","author":"Guo","year":"2016","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jare.2021.10.010_b0655","doi-asserted-by":"crossref","first-page":"41363","DOI":"10.18632\/oncotarget.9133","article-title":"COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo","volume":"7","author":"Salim","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jare.2021.10.010_b0660","article-title":"Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines","volume":"13","author":"Vareki","year":"2018","journal-title":"PloSOne"},{"key":"10.1016\/j.jare.2021.10.010_b0665","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1039\/b906679a","article-title":"Chemistry and biology of siderophores","volume":"27","author":"Hider","year":"2010","journal-title":"Nat Prod Rep"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322100206X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S209012322100206X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:52:16Z","timestamp":1761857536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S209012322100206X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":133,"alternative-id":["S209012322100206X"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2021.10.010","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing microbial iron chelators to develop innovative therapeutic agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}